Virology division end date??

Discussion in 'Bristol-Myers Squibb' started by anonymous, Dec 7, 2016 at 11:57 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Again, lazy sloths as they aren't willing to look outside their comfy zone of the past 10-15 years. Try re-inventing yourself every once in awhile.
     

  2. anonymous

    anonymous Guest

    The rude awakening is that no employers wants HIV or ID reps -they won't have any relevant experience in a competitive job market
     
  3. anonymous

    anonymous Guest

    Well said, exactly the sentiment out there. Those of you who think your decade plus of dedication to the HIV field sets you apart, you're dreaming. For the most part, you're so far behind the pack, you'll have egg on your face in an interview for a relevant position trying to articulate why you stayed with a has-been market place.
     
  4. anonymous

    anonymous Guest

    You're absolutely right. Nobody has HIV anymore. It's not even a has-been marketplace, it's a never-was. It's all a government conspiracy!
     
  5. anonymous

    anonymous Guest

    Yes there is a Virology division.
    Virology accounted for over $4 billion or 222% of revenues in 2016.
     
  6. anonymous

    anonymous Guest

    Yes there is a Virology division.
    Virology accounted for over $4 billion or 22% of revenues in 2016.
     
  7. anonymous

    anonymous Guest

    Just never hear anything about this group
     
  8. anonymous

    anonymous Guest

    don't blame reps you donut boy! use that mountain scent Gain on your face
     
  9. anonymous

    anonymous Guest

    Always been that way, even when virology was contributing the most. Sad to see what it's become
     
  10. anonymous

    anonymous Guest

    China Approves Bristol-Myers Squibb’s Dual-Drug Hepatitis C Treatment.
     
  11. anonymous

    anonymous Guest

    Who cares. HCV gone. HIV soon to follow. Unless they want to transfer the sales force to China.
     
  12. anonymous

    anonymous Guest

    “We are proud to build on our legacy, infrastructure and experience in treating viral hepatitis throughout Asia by bringing Daklinza-based regimens to patients in China,” said Murdo Gordon, executive vice president and chief commercial officer, Bristol-Myers Squibb.
     
  13. anonymous

    anonymous Guest

    Did he also say that will have any effect on the virology salesforce in the US? I didn't think so.
     
  14. anonymous

    anonymous Guest

    Ximency (daclatasvir + asunaprevir + beclabuvir) in Japan, aiming to regain its lost ground in the genotype 1 market.
     
  15. anonymous

    anonymous Guest

    Only one of those three saw the light of day in the US and at less than 2 years after approval of it, it has already become obsolete.
     
  16. anonymous

    anonymous Guest

    Around $1.1 billion in Virology revenues in 1Q2017.
    Not bad for a division that was closed 2 years ago.
     
  17. anonymous

    anonymous Guest

    Date of euthanasia was put out today.
     
  18. anonymous

    anonymous Guest

    Who even knew BMS had a virology division????
     
  19. anonymous

    anonymous Guest

    HA HA!!!!
    Indeed....like R&D.....
    Mostly "make something out of this crap we've already paid for"!!!!!!
     
  20. anonymous

    anonymous Guest

    Lambda